NRSNW News

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense Provides Business Update and Progress for the First Half of 2026

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS